Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks